New eye drug aims to block two causes of vision loss at once
NCT ID NCT07520318
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an investigational drug called OCUL101 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision and can lead to blindness. OCUL101 targets two proteins involved in the disease to reduce abnormal blood vessel growth and inflammation. About 255 adults aged 50-89 will receive either OCUL101 or the standard treatment Eylea to see which is safer and more effective at preserving vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact